Angelini Pharma Collaborates with JCR Pharmaceuticals
Friday, May 12, 2023
Angelini Pharma, part of the privately owned Angelini Industries, and JCR Pharmaceuticals announced that they entered into an exclusive global development and commercialisation agreement for the development of novel biologic therapies that applies J-Brain Cargo®, blood-brain-barrier penetrating technology, for the treatment of epilepsy applying undisclosed effectors.
Under the terms of the agreement, JCR will receive reimbursement of research expenses, upfront payment and will also be eligible to receive additional development and commercial milestones up to US$505.5 million, as well as tiered royalties on post-approval net sales.
JCR and Angelini Pharma will collaboratively lead the discovery and pre-clinical development efforts for the identification of brain-penetrant biologic therapeutics using JCR’s proprietary blood-brain-barrier technology, J-Brain Cargo®. This technology allows the delivery of biotherapeutics into the central nervous system via a mechanism called receptor-mediated transcytosis.
Through this strategic collaboration with JCR, combines the strengths to explore the use of biologics in the field and accelerate the discovery of critically needed treatment options for people with epilepsy.
